Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec 8;82(1):136–141. doi: 10.1054/bjoc.1999.0890

p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer

H A Phillips 1,2, G C W Howard 1,2, W R Miller 2
PMCID: PMC2363182  PMID: 10638980

Abstract

The diagnosis and follow-up of patients with bladder cancer rely on invasive procedures (cystoscopy with biopsy). Polymerase chain reaction (PCR)-based technologies may allow the sensitive detection of cancer-related genetic mutations in exfoliated tumour material, potentially allowing the development of less invasive techniques. This pilot study investigated the feasibility of detecting mutations in exons 5–8 of the p53 gene using single-stranded conformational polymorphism (SSCP) analysis in bladder-washing specimens from patients with bladder cancer. Bladder-washing samples (31) were collected from patients (27) with bladder cancer. An abnormal additional SSCP band was detected in five samples from five different patients suggesting the presence of a p53 mutation. In all five cases the same abnormal SSCP pattern was demonstrated in samples of the corresponding bladder tumour. In one case bladder washings were available from the same patient on two separate occasions with one washing demonstrating a mutation and the other not. In two further cases a mutation was demonstrated in the bladder tumour but not in the corresponding washing. It is concluded that it is possible to detect and characterize p53 mutations in bladder-washing samples from patients with bladder cancer. Improved sensitivity in detecting mutations in a sample containing a mixture of normal and malignant cells may lead to the clinical applicability of molecular methods of disease monitoring. © 2000 Cancer Research Campaign

Keywords: p53, mutations, bladder cancer, bladder washings

Full Text

The Full Text of this article is available as a PDF (192.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., Kaye S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer. 1993 Oct 21;55(4):678–684. doi: 10.1002/ijc.2910550428. [DOI] [PubMed] [Google Scholar]
  2. Esrig D., Spruck C. H., 3rd, Nichols P. W., Chaiwun B., Steven K., Groshen S., Chen S. C., Skinner D. G., Jones P. A., Cote R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993 Nov;143(5):1389–1397. [PMC free article] [PubMed] [Google Scholar]
  3. Fitzgerald J. M., Ramchurren N., Rieger K., Levesque P., Silverman M., Libertino J. A., Summerhayes I. C. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst. 1995 Jan 18;87(2):129–133. doi: 10.1093/jnci/87.2.129. [DOI] [PubMed] [Google Scholar]
  4. Fujimoto K., Yamada Y., Okajima E., Kakizoe T., Sasaki H., Sugimura T., Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992 Mar 15;52(6):1393–1398. [PubMed] [Google Scholar]
  5. Hermansen D. K., Reuter V. E., Whitmore W. F., Jr, Fair W. R., Melamed M. R. Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). J Urol. 1988 Dec;140(6):1394–1396. doi: 10.1016/s0022-5347(17)42053-2. [DOI] [PubMed] [Google Scholar]
  6. Levesque P., Ramchurren N., Saini K., Joyce A., Libertino J., Summerhayes I. C. Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer. 1993 Nov 11;55(5):785–790. doi: 10.1002/ijc.2910550516. [DOI] [PubMed] [Google Scholar]
  7. Maier U., Simak R., Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol. 1995 Apr;48(4):314–317. doi: 10.1136/jcp.48.4.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mao L., Schoenberg M. P., Scicchitano M., Erozan Y. S., Merlo A., Schwab D., Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996 Feb 2;271(5249):659–662. doi: 10.1126/science.271.5249.659. [DOI] [PubMed] [Google Scholar]
  9. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  10. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989 Nov;5(4):874–879. doi: 10.1016/0888-7543(89)90129-8. [DOI] [PubMed] [Google Scholar]
  11. Prosser J., Thompson A. M., Cranston G., Evans H. J. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene. 1990 Oct;5(10):1573–1579. [PubMed] [Google Scholar]
  12. Sidransky D., Frost P., Von Eschenbach A., Oyasu R., Preisinger A. C., Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737–740. doi: 10.1056/NEJM199203123261104. [DOI] [PubMed] [Google Scholar]
  13. Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S. R., Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706–709. doi: 10.1126/science.2024123. [DOI] [PubMed] [Google Scholar]
  14. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  15. Smith T. A., Whelan J., Parry P. J. Detection of single-base mutations in a mixed population of cells: a comparison of SSCP and direct sequencing. Genet Anal Tech Appl. 1992 Oct-Dec;9(5-6):143–145. doi: 10.1016/1050-3862(92)90039-8. [DOI] [PubMed] [Google Scholar]
  16. Steiner G., Schoenberg M. P., Linn J. F., Mao L., Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 1997 Jun;3(6):621–624. doi: 10.1038/nm0697-621. [DOI] [PubMed] [Google Scholar]
  17. Vet J. A., Witjes J. A., Marras S. A., Hessels D., van der Poel H. G., Debruyne F. M., Schalken J. A. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res. 1996 Jun;2(6):1055–1061. [PubMed] [Google Scholar]
  18. Walther P. J. The role of flow cytometry in the management of bladder cancer. Hematol Oncol Clin North Am. 1992 Feb;6(1):81–98. [PubMed] [Google Scholar]
  19. Winship P. R. An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res. 1989 Feb 11;17(3):1266–1266. doi: 10.1093/nar/17.3.1266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wu J. K., Ye Z., Darras B. T. Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am J Hum Genet. 1993 Jun;52(6):1273–1275. [PMC free article] [PubMed] [Google Scholar]
  21. Xu X., Stower M. J., Reid I. N., Garner R. C., Burns P. A. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res. 1996 Oct;2(10):1795–1800. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES